ARS Pharmaceuticals (SPRY) Payables (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Payables of $48.3 million for Q1 2026, up 27.18% sequentially from $37.9 million in Q4 2025, and up 78.69% YoY from $27.0 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Payables (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Payables for 7 years, with the latest figure at $48.3 million in Q1 2026.
- Quarterly Payables rose 78.69% year-over-year to $48.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.3 million (up 78.69% YoY) and the FY2025 annual result came in at $37.9 million, up 66.14% from the prior year.
- Payables improved to $48.3 million in Q1 2026 per SPRY's latest filing, from $37.9 million in the prior quarter.
- Over five years, Payables peaked at $49.8 million in Q3 2025 and troughed at $126000.0 in Q3 2022.
- A 5-year average of $17.6 million and a median of $9.8 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables plunged 92.67% in 2022, then surged 8586.51% in 2023.
- Over 5 years, Payables stood at $4.9 million in 2022, then slumped by 56.32% to $2.2 million in 2023, then jumped by 960.4% to $22.8 million in 2024, then jumped by 66.14% to $37.9 million in 2025, then gained by 27.18% to $48.3 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $48.3 million, $37.9 million, and $49.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 59.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.73 Mn |
| Mar 31, 2026 | 48.26 Mn |
| Dec 31, 2025 | 37.95 Mn |
| Sep 30, 2025 | 49.77 Mn |
| Jun 30, 2025 | 44.26 Mn |
| Mar 31, 2025 | 27.01 Mn |
| Dec 31, 2024 | 22.84 Mn |
| Sep 30, 2024 | 16.52 Mn |
| Jun 30, 2024 | 6.57 Mn |
| Mar 31, 2024 | 3.50 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 10.95 Mn |
| Jun 30, 2023 | 9.82 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 4.93 Mn |
| Sep 30, 2022 | 126,000.00 |
| Jun 30, 2022 | 2.11 Mn |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 6.59 Mn |
| Sep 30, 2021 | 1.72 Mn |